Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment
Issued Date
2024-01-01
Resource Type
ISSN
01406736
eISSN
1474547X
Scopus ID
2-s2.0-85198601101
Journal Title
The Lancet
Rights Holder(s)
SCOPUS
Bibliographic Citation
The Lancet (2024)
Suggested Citation
Zuberbier T., Ensina L.F., Giménez-Arnau A., Grattan C., Kocatürk E., Kulthanan K., Kolkhir P., Maurer M. Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment. The Lancet (2024). doi:10.1016/S0140-6736(24)00852-3 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/99773
Title
Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment
Corresponding Author(s)
Other Contributor(s)
Abstract
Chronic urticaria is a common and debilitating mast cell-driven skin disease presenting with itchy wheals, angio-oedema, or both. Chronic urticaria is classified as spontaneous (without definite triggers) and inducible (with definite and subtype-specific triggers; eg, cold or pressure). Current management guidelines recommend step-up administration of second-generation H1-antihistamines to four-fold the approved dose, followed by omalizumab and ciclosporin. However, in many patients, chronic urticaria does not respond to this linear approach due to heterogeneous underlying mechanisms. A personalised endotype-based approach is emerging based on the identification of autoantibodies and other drivers of urticaria pathogenesis. Over the past decade, clinical trials have presented promising options for targeted treatment of chronic urticaria with the potential for disease modification, including Bruton's tyrosine kinase inhibitors, anti-cytokine therapies, and mast cell depletion. This Therapeutics article focuses on the evidence for these novel drugs and their role in addressing an unmet need for personalised management of patients with chronic urticaria.